Hormonal
Rapamycin extends maximal lifespan in mice primarily by suppressing lethal neoplastic disease (cancer) rather than by slowing the fundamental rate of biological aging.
While rapamycin extends mouse lifespan, current evidence suggests this is due to cancer suppression, not a general slowing of aging. Symptomatic benefits (like improved cognition) are observed but appear to be independent of age. Human translation requires caution as cancer risk profiles differ, and symptomatic benefits may not imply slowed biological aging.
Current available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
Why this rating
Based on multiple high-quality longitudinal studies in genetically heterogeneous and inbred mouse strains with cause-of-death analysis.
Source
Longevity, aging and rapamycin
Dan Ehninger et al. · Cellular and Molecular Life Sciences · 2014
DOI 10.1007/s00018-014-1677-1
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →